Stifel Maintains Buy on Biomarin Pharmaceutical, Raises Price Target to $112
Portfolio Pulse from Benzinga Newsdesk
Stifel analyst Paul Matteis maintains a Buy rating on Biomarin Pharmaceutical (NASDAQ:BMRN) and raises the price target from $108 to $112.
August 06, 2024 | 11:25 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Stifel analyst Paul Matteis maintains a Buy rating on Biomarin Pharmaceutical and raises the price target from $108 to $112.
The Buy rating and increased price target from a reputable analyst at Stifel is likely to positively influence investor sentiment and drive short-term price appreciation for Biomarin Pharmaceutical.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100